LinkedIn Profile

Access Capstone Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
otc:caps 1448132 Apr 14th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 14th, 2024 01:58AM Apr 14th, 2024 01:58AM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 13th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 13th, 2024 01:19AM Apr 13th, 2024 01:38PM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 12th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 12th, 2024 01:30AM Apr 12th, 2024 10:39AM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 11th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 11th, 2024 03:41AM Apr 11th, 2024 01:22PM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 10th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 10th, 2024 01:26AM Apr 10th, 2024 07:26PM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 9th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 9th, 2024 01:54AM Apr 9th, 2024 12:09PM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 8th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 8th, 2024 02:31AM Apr 8th, 2024 09:05PM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 7th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 7th, 2024 02:08AM Apr 7th, 2024 02:08AM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 6th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 6th, 2024 01:45AM Apr 6th, 2024 01:45AM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics
otc:caps 1448132 Apr 5th, 2024 12:00AM Capstone Therapeutics 144 8.00 Open Apr 5th, 2024 04:28AM Apr 5th, 2024 04:28AM Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes. Open Open Capstone Therapeutics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.